Literature DB >> 25458445

Incidence and predictors of sarcopenia onset in community-dwelling elderly Japanese women: 4-year follow-up study.

Hunkyung Kim1, Takao Suzuki2, Miji Kim3, Narumi Kojima3, Yuko Yoshida3, Hirohiko Hirano3, Kyoko Saito3, Hajime Iwasa4, Hiroyuki Shimada2, Erika Hosoi3, Hideyo Yoshida3.   

Abstract

OBJECTIVES: Several studies have explored the prevalence and risk factors of sarcopenia, but they have been based on cross-sectional data. The objective of this study was to determine the incidence and predictors of the onset of sarcopenia over 4 years in community-dwelling elderly women.
DESIGN: Four-year longitudinal follow-up study.
SETTING: Urban community in Tokyo, Japan. PARTICIPANTS: A total of 538 nonsarcopenic women older than 75 years. MEASUREMENTS: Body composition was determined by bioelectrical impedance analysis. Functional fitness measurements, including grip strength, usual walking speed, timed up and go (TUG), and interview surveys were conducted at baseline and 4-year follow-up. Blood samples were obtained to analyze serum albumin and hemoglobin A1c, and kidney function was analyzed using serum creatinine and cystatin C. Sarcopenia was defined based on the criteria suggested by the European Working Group on Sarcopenia in Older People, and the development of all stages, that is, presarcopenia, sarcopenia, and severe sarcopenia as well as the components of sarcopenia skeletal muscle index (SMI), grip strength, and walking speed, were analyzed.
RESULTS: The incidence of total sarcopenia was 39.6% (presarcopenia 23.8%, sarcopenia 11.2%, severe sarcopenia 4.6%). Older age was significantly predictive of the development of presarcopenia and severe sarcopenia. Body mass index (BMI) lower than 21.0 kg/m(2) was significantly predictive of the development of all stages of sarcopenia, as well as declines in SMI, grip strength, and walking speed. Slow TUG was a predictor of the development of presarcopenia and severe sarcopenia. Increased calf circumference showed protective effects from the development of all stages of sarcopenia. Greater albumin levels also showed lower risk of declines in SMI, walking speed, and development of presarcopenia. Cystatin C was positively associated with the development of severe sarcopenia (odds ratio 1.83, 95% confidence interval 1.08-3.12). Heart disease and hyperlipidemia history were associated with presarcopenia and sarcopenia, respectively.
CONCLUSION: Age, BMI, calf circumference, and TUG were consistent predictors of the various stages and components of sarcopenia. The data also suggest that cystatin C was associated with higher odds of incident severe sarcopenia, and further study into kidney function and onset of sarcopenia in large populations is needed.
Copyright © 2015 AMDA – The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Sarcopenia; elderly women; incidence; predictor

Mesh:

Substances:

Year:  2014        PMID: 25458445     DOI: 10.1016/j.jamda.2014.10.006

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  30 in total

1.  The Effect of Age upon the Interrelationship of BMI and Inpatient Health Outcomes.

Authors:  C Woolley; C Thompson; P Hakendorf; C Horwood
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Incidence, Risk Factors, and the Protective Effect of High Body Mass Index against Sarcopenia in Suburb-Dwelling Elderly Chinese Populations.

Authors:  P Han; J Zhao; Q Guo; J Wang; W Zhang; S Shen; X Wang; R Dong; Y Ma; L Kang; L Fu; L Jia; X Han; Z He; Y Bao; L Wang; K Niu
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

3.  Exercise and/or Dietary Varieties and Incidence of Frailty in Community-Dwelling Older Women: A 2-Year Cohort Study.

Authors:  Y Osuka; N Kojima; Y Yoshida; M Kim; C W Won; T Suzuki; H Kim
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

4.  The Association between Sarcopenia and Prealbumin Levels among Elderly Chinese Inpatients.

Authors:  Q Chen; Q Hao; Y Ding; B Dong
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

5.  Sarcopenia and mortality risk in community-dwelling Brazilian older adults.

Authors:  Cristina Camargo Pereira; Valéria Pagotto; Cesar de Oliveira; Erika Aparecida Silveira
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

6.  Physical activity and incidence of sarcopenia: the population-based AGES-Reykjavik Study.

Authors:  Donja M Mijnarends; Annemarie Koster; Jos M G A Schols; Judith M M Meijers; Ruud J G Halfens; Vilmundur Gudnason; Gudny Eiriksdottir; Kristin Siggeirsdottir; Sigurdur Sigurdsson; Pálmi V Jónsson; Osorio Meirelles; Tamara Harris
Journal:  Age Ageing       Date:  2016-05-17       Impact factor: 10.668

7.  The prevalence of sarcopenia risk and associated factors in patients aged 65-79 years living in a district of Izmir province of Turkey.

Authors:  Erdem Erkoyun; Reyhan Uçku
Journal:  Turk J Phys Med Rehabil       Date:  2020-03-03

8.  Accelerometer-determined physical activity, muscle mass, and leg strength in community-dwelling older adults.

Authors:  Yi Chao Foong; Nabil Chherawala; Dawn Aitken; David Scott; Tania Winzenberg; Graeme Jones
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-10-15       Impact factor: 12.910

9.  The increased risk of sarcopenia in patients with cardiovascular risk factors in Suburb-Dwelling older Chinese using the AWGS definition.

Authors:  Peipei Han; Hairui Yu; Yixuan Ma; Li Kang; Liyuan Fu; Liye Jia; Xiaoyu Chen; Xing Yu; Lin Hou; Lu Wang; Wen Zhang; Haifang Yin; Kaijun Niu; Qi Guo
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

10.  Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study.

Authors:  Thomas Yates; Francesco Zaccardi; Nafeesa N Dhalwani; Melanie J Davies; Kishan Bakrania; Carlos A Celis-Morales; Jason M R Gill; Paul W Franks; Kamlesh Khunti
Journal:  Eur Heart J       Date:  2017-11-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.